Provectus Biopharmaceuticals

Developing Safe, Affordable, and Accessible Immunotherapy Medicines that Maximize Curative Impact

Provectus Biopharmaceuticals' vision is to make our innovative medicines equitably accessible and financially affordable to patients and their families and caregivers around the world.


Provectus is a clinical-stage biotechnology company developing immunotherapy medicines based on small molecules called halogenated xanthenes, the entire class of which is owned by our company. Provectus' lead molecule is called rose bengal disodium. Based on different formulations and routes of administration, our clinical and non-clinical data indicate how Provectus’ drug platform may treat different indications across a diverse range of disease areas that include oncology, dermatology, hematology, virology, microbiology, and ophthalmology.


Learn More